Volume 18, Number 1—January 2012
CME ACTIVITY - Research
Accelerating Control of Pertussis in England and Wales
, Gayatri Amirthalingam, Nick Andrews, Norman K. Fry, Robert C. George, Timothy Harrison, and Elizabeth Miller
Table 5
Estimated effectiveness of a 3-dose pertussis vaccine schedule among case-patients with serology-confirmed pertussis, by vaccine cohort and age group, England, 2002–2009*
| Vaccine cohort† | Age group of pertussis case-patients |
|||||||
|---|---|---|---|---|---|---|---|---|
| 12–39 mo |
5–9 y |
10–16 y |
||||||
| No. vaccinated/ no. total | % VE (95% CI) | No. vaccinated/ no. total | % VE (95% CI) | No. vaccinated/ no. total | % VE (95% CI) | |||
| 1 | – | – | – | – | 28/29 | −41.3 (−5,679 to 76.6) | ||
| 2 | 1/1 | – | 88/108 | 90.4‡ (83.4 to 94.1) | 463/500 | 72.1‡ (59.9 to 80.1) | ||
| 3 | 2/2 | – | 26/33 | 91.0§ (75.4 to 96.2) | – | – | ||
| 4 | 2/4 | 97.7 (67.6 to 99.8) | 4/5 | 90.9§ (−348 to 99.1) | – | – | ||
| 5 | 21/25 | 69 (−24.2 to 89.5) | – | – | – | – | ||
| Overall total | 26/32 | 77.8 (34.2 to 91.1) | 118/146 | 90.5 (85.1 to 93.8) | 491/529 | 69.3 (56.1 to 78.0) | ||
*VE, vaccine effectiveness; –, no cases that met the criteria were identified during 2002–2009 and, therefore, VE could not be calculated, or case nos. were too small for calculation purposes.
†Vaccine cohorts: cohort 1, received diphtheria/tetanus/whole-cell pertussis vaccine (DTwP) at 3, 5, and 11 mo of age; cohort 2, received DTwP at 2, 3, and 4 mo of age; cohort 3, received DTwP or DTaP3 (DT/3-component acellular pertussis vaccine) at 2, 3, and 4 mo of age; cohort 4, received DTwP at 2, 3, 4 mo of age; cohort 5, received DTaP5 at 2, 3, and 4 mo of age.
‡VE mainly reflects 3 doses; however, some eligible children had received 4 doses.
§Some children were eligible for a booster vaccination; thus, VE is for 3 or 4 doses.